Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Germany | 544.3 | 571.9 | 681.4 | 332.9 | | | | |
| Magnetic Technologies | 495.0 | 522.6 | 631.6 | 276.1 | | | | |
| Specialty Chemicals | 316.1 | 318.6 | 323.6 | 375.1 | 462.7 | 401.8 | 546.7 | |
| United States | 263.3 | 296.2 | 324.9 | 318.4 | 312.4 | 153.5 | 280.3 | |
| Other | | | | 117.1 | 421.5 | 316.3 | 909.9 | |
| Total revenues | 1,067.5 | 1,157.5 | 1,544.4 | 1,419.6 | 1,196.6 | 871.7 | 1,736.8 | 1,021.5 |
| Revenue growth [+] | -7.8% | -25.1% | 8.8% | 18.6% | 37.3% | -49.8% | 70.0% | 54.7% |
| Germany | -4.8% | -16.1% | 104.7% | | | | | |
| Magnetic Technologies | -5.3% | -17.3% | 128.8% | | | | | |
| Specialty Chemicals | -0.8% | -1.5% | -13.7% | -18.9% | 15.2% | -26.5% | | |
| United States | -11.1% | -8.8% | 2.0% | 1.9% | 103.4% | -45.2% | | |
| Other | -0.1% | 7.4% | -12.9% | -44.9% | 14.3% | -21.0% | | |
| Cost of goods sold | 829.3 | 899.1 | 1,300.8 | 1,178.7 | 912.0 | 705.9 | 1,384.3 | 708.3 |
| Gross profit | 238.2 | 258.4 | 243.6 | 240.9 | 284.7 | 165.8 | 352.5 | 313.2 |
| Gross margin | 22.3% | 22.3% | 15.8% | 17.0% | 23.8% | 19.0% | 20.3% | 30.7% |
| Selling, general and administrative | 207.9 | 217.3 | 251.2 | 219.4 | 162.0 | 134.0 | 166.1 | 117.0 |
| Other operating expenses | -1.7 | 98.6 | | -19.4 | | -4.7 | | |
| EBITDA [+] | 99.5 | 16.4 | 76.7 | 105.9 | 176.7 | 90.3 | 242.5 | |
| EBITDA growth | 506.7% | -78.6% | -27.6% | -40.1% | 95.8% | -62.8% | | |
| EBITDA margin | 9.3% | 1.4% | 5.0% | 7.5% | 14.8% | 10.4% | 14.0% | |
| Depreciation and amortization | 67.5 | 73.9 | 84.3 | 65.0 | 54.1 | 53.8 | 56.1 | |
| EBIT [+] | 32.0 | -57.5 | -7.6 | 40.9 | 122.6 | 36.5 | 186.4 | 196.2 |
| EBIT growth | -155.7% | 656.6% | -118.6% | -66.7% | 235.8% | -80.4% | -5.0% | 160.7% |
| EBIT margin | 3.0% | -5.0% | -0.5% | 2.9% | 10.2% | 4.2% | 10.7% | 19.2% |
| Non-recurring items [+] | 197.1 | -98.6 | -2.9 | 9.7 | | 37.5 | 8.8 | |
| Asset impairment | 195.4 | | | | | 37.5 | 8.8 | |
| Interest expense, net [+] | 2.6 | 12.3 | 49.7 | 22.1 | 4.3 | -0.2 | -0.3 | -11.6 |
| Interest expense | 2.6 | 12.3 | 49.7 | 22.1 | 5.3 | 0.7 | 1.6 | 7.8 |
| Interest income | | | | | 0.9 | 0.9 | 1.9 | 19.4 |
| Other income (expense), net [+] | -5.1 | -91.6 | 5.8 | 17.5 | -11.0 | -0.3 | -5.7 | -9.6 |
| Gain (loss) on foreign currency transactions | -6.5 | 8.0 | -0.8 | 11.1 | -10.7 | 0.0 | -3.7 | |
| Other | -0.3 | 12.0 | 6.6 | 6.4 | -0.3 | -0.3 | -1.9 | |
| Pre-tax income | -172.8 | -62.8 | -48.6 | 26.6 | 107.3 | -1.1 | 172.3 | 198.3 |
| Income taxes | -0.5 | 10.7 | -3.2 | -17.9 | 29.7 | 20.9 | 16.1 | -76.3 |
| Tax rate | 0.3% | | 6.6% | | 27.6% | | 9.3% | |
| Minority interest | | -1.8 | -7.1 | 4.7 | -5.0 | -2.6 | 21.3 | -10.4 |
| Earnings from continuing ops | -172.3 | -71.7 | -38.3 | 39.8 | 82.6 | -41.3 | 134.9 | 111.6 |
| Earnings from discontinued ops | -0.3 | -12.3 | -0.4 | 2.2 | 0.7 | 1.5 | 0.1 | 135.3 |
| Net income | -172.6 | -84.0 | -38.7 | 42.0 | 83.4 | -39.8 | 135.0 | 246.9 |
| Net margin | -16.2% | -7.3% | -2.5% | 3.0% | 7.0% | -4.6% | 7.8% | 24.2% |
| |
| Basic EPS [+] | ($5.54) | ($2.27) | ($1.20) | $1.28 | $2.72 | ($1.37) | $4.48 | $3.73 |
| Growth | 144.2% | 89.0% | -193.8% | -52.9% | -298.8% | -130.5% | 20.2% | 363.2% |
| Diluted EPS [+] | ($5.54) | ($2.27) | ($1.20) | $1.28 | $2.70 | ($1.37) | $4.44 | $3.68 |
| Growth | 144.2% | 89.0% | -194.1% | -52.8% | -298.0% | -130.7% | 20.6% | 361.3% |
| |
| Dividends per share | $0.30 | | | | | | | |
| |
| Shares outstanding (basic) [+] | 31.1 | 31.6 | 31.9 | 31.1 | 30.4 | 30.2 | 30.1 | 29.9 |
| Growth | -1.6% | -0.9% | 2.6% | 2.2% | 0.6% | 0.4% | 0.6% | 2.0% |
| Shares outstanding (diluted) [+] | 31.1 | 31.6 | 31.9 | 31.2 | 30.6 | 30.2 | 30.4 | 30.3 |
| Growth | -1.6% | -0.9% | 2.2% | 2.1% | 1.1% | -0.4% | 0.3% | 2.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|